Results 261 to 270 of about 209,459 (341)
Observable score for bleeding after colorectal endoscopic mucosal resection. [PDF]
Nakazawa H +14 more
europepmc +1 more source
ABSTRACT Chronic mesenteric ischemia (CMI) secondary to extensive paravisceral atherosclerosis is a rare but challenging vascular condition, often presenting with postprandial abdominal pain, weight loss, and claudication due to impaired blood flow. While surgical bypass is a standard treatment, it carries significant risks, particularly in patients ...
Dipankar Mukherjee +2 more
wiley +1 more source
Is Aortic Balloon Occlusion Effective to Reduce Blood Loss During Lower Lumbar Tumor Resection?
ABSTRACT Purpose In this study, we evaluated the efficacy and safety of using an aortic balloon to control blood loss during lower lumbar tumor resection. Methods We retrospectively reviewed 82 patients with tumors involving the lower lumbar spine (L4, L5, or Both), who were treated at our center from July 2015 to September 2023.
Jiacheng Chen +7 more
wiley +1 more source
Effectiveness and safety of an absorbable modified polymer starch powder hemostat versus usual care in gynecology procedures: A prospective, multi-center, and randomized study. [PDF]
Ponce J +7 more
europepmc +1 more source
Abstract Endogenous oxytocin plays an important role in lactation, but its effectiveness as an exogenous galactagogue has been modest due to dose‐limiting side effects related to off‐target effects at the vasopressin V2 receptor. Merotocin (FE 202767) is a short‐acting peptidic oxytocin receptor agonist with the potential to aid mothers experiencing ...
Yu Bagger +4 more
wiley +1 more source
Misplacement of a femoral venous catheter into the ascending lumbar vein: A case report and first use of balloon catheter compression hemostasis. [PDF]
Li X +5 more
europepmc +1 more source
Endoscopic hemostasis treatment for bleeding peptic ulcers
Somchai Luangjaru
openalex +2 more sources
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou +12 more
wiley +1 more source

